Loading...
Please wait, while we are loading the content...
Similar Documents
Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance
| Content Provider | Scilit |
|---|---|
| Author | Wang, Guiliang Liu, Yan Qiu, Ping Xu, Linfang Wen, Ping Wen, Jianbo Xiao, Xianzhong Zhou, Shu-Feng |
| Copyright Year | 2015 |
| Description | Journal: Drug design, development and therapy |
| Abstract | Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance Guiliang Wang,1,2 Yan Liu,2 Ping Qiu,1 Shu-Feng Zhou,3,4 Linfang Xu,1 Ping Wen,1 Jianbo Wen,1 Xianzhong Xiao5 1Department of Digestive Internal Medicine, Gannan Medical University Pingxiang Hospital, Pingxiang, People’s Republic of China; 2Department of Digestive Internal Medicine, 307 Hospital of PLA, Beijing, People’s Republic of China; 3Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL, USA; 4Guizhou Provincial Key Laboratory for Regenerative Medicine, Stem Cell and Tissue Engineering Research Center and Sino-US Joint Laboratory for Medical Sciences, Guiyang Medical University, Guiyang, People’s Republic of China; 5Laboratory of Shock, Department of Pathophysiology, Xiangya School of Medicine, Central South University, Changsha, People’s Republic of China The purpose of this study was to analyze the cost-effectiveness of lamivudine (LMV), telbivudine (LdT), and entecavir (ETV) in treatment of chronic hepatitis B with adefovir dipivoxil (ADV) resistance. Two hundred and fifty-two patients were recruited and screened for resistance to ADV and randomly assigned into three groups: LMV + ADV, LdT + ADV, and ETV + ADV. The ratio of biochemical response, virological response, seroconversion of hepatitis Be antigen (HBeAg)/hepatitis Be antibody (HBeAb), viral breakthrough, and the cost and effectiveness of treatments were analyzed. A comparison of the results of the ratio of biochemical response, virological response and seroconversion of HBeAg/HBeAb, showed no statistical difference between the three groups, with the economic cost of LMV + ADV the lowest, LdT + ADV the middle, and ETV + ADV the highest. The side effects of the three plans are all rare and tolerable. LMV + ADV is the optimal rescue strategy, and LdT + ADV the alternative selection in the economically less developed regions, while ETV + ADV was used in the economically developed regions. Keywords: chronic hepatitis B, adefovir dipivoxil, lamivudine, telbivudine, entecavir, resistance |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4459610/pdf https://www.dovepress.com/getfile.php?fileID=25276 |
| Ending Page | 2846 |
| Page Count | 8 |
| Starting Page | 2839 |
| e-ISSN | 11778881 |
| DOI | 10.2147/dddt.s73150 |
| Journal | Drug design, development and therapy |
| Volume Number | 9 |
| Language | English |
| Publisher | Informa UK Limited |
| Publisher Date | 2015-06-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: Drug design, development and therapy Gastroenterology and Hepatology Adefovir Dipivoxil Chronic Hepatitis B |
| Content Type | Text |
